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Summary
Serotonin (5-Hydroxytryptamine [5-HT]) plays an im-
portant role in gastrointestinal (GI) motility and sensation, and 
abnormal levels have been shown in patients with irritable bowel 
syndrome (IBS).
1,2 Drugs acting on 5-HT receptors have the po-
tential to reduce the smooth muscle spasm, abdominal pain, and 
changes in bowel habit in IBS. 
Recently, Lee et al
3 assessed the efficacy and safety of ramo-
setron, a 5-HT3 receptor antagonist, compared with mebeverine 
in male patients with diarrhea-predominant IBS (IBS-D). This 
study was performed in a multicenter, randomized, open-label, 
parallel-group, non-inferiority comparative design. A total of 343 
male patients with IBS-D were randomized to either ramosetron 
5 μg once daily or mebeverine 135 mg 3 times daily for 4 weeks. 
The weekly responder rates for global IBS symptoms, ab-
dominal pain/discomfort and abnormal bowel habits in the ra-
mosteron and mebeverine groups significantly increased during 
the treatment period (P < 0.001). The severity scores of abdomi-
nal pain/discomfort and urgency, the stool form scores and the 
stool frequency recorded daily were reduced significantly in both 
treatment arms, compared with the baselines (P < 0.001). There 
were no significant differences in the weekly responder rates 
(37% vs 38% at 4-week) and in the adverse event profiles be-
tween the ramosetron and mebeverine groups. Neither severe 
constipation nor ischemic colitis was reported. The authors con-
cluded that the ramosetron 5 μg once daily was as effective as me-
beverine 3 times daily in male patients with IBS-D.
Comment
IBS is the most common functional bowel disorder and is 
characterized by recurrent abdominal pain and discomfort with 
altered bowel habits.
4 IBS may lead to impaired social and per-
sonal functions as well as deterioration in the quality of life of af-
fected individuals. While the pathophysiology of IBS is still un-
clear, altered bowel motility, visceral hypersensitivity, immune 
activation, enteric neuromuscular dysfunction, abnormal brain-gut 
interactions, and alteration in the gut microbiome have been 
hypothesized.
5 Although the concept of IBS has been established 
for several decades, current available therapies remain unsat-
isfactory and provide only symptomatic relief at best for many pa-
tients with IBS.Ramosetron in Male Patients With IBS-D
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Serotonin (5-HT) signaling in the GI tract is known to con-
trol a range of functions such as motility, sensation and secretion.
1,2 
Some evidence suggests that drugs regulating the 5-HT signal-
ing are effective in patients with IBS.
6-9 Alosetron, a 5-HT3 an-
tagonist, was first evaluated in the 1990s, and initial trial data 
suggested that it was a promising drug for the treatment of 
IBS-D, particularly in female patients. However, because of the 
serious adverse events, such as severe constipation and ischemic 
colitis, reported in IBS patients treated with alosetron, it is avail-
able only in the USA with a limited access program for women 
with severe IBS-D refractory to conventional therapy.
10 Recently, 
ramosetron, one of the 5-HT3 receptor antagonists, have been re-
ported to be effective for patients with IBS-D in 2 clinical 
trials.
11,12 The administration of ramosetron 5 μg once daily had 
beneficial effects on IBS symptoms of male patients with IBS-D, 
compared with placebo. 
Lee et al
3 assessed the efficacy of ramosetron compared with 
mebeverine, an antispasmodic agent, in male patients with 
IBS-D. Ramosetron had similar therapeutic efficacy to mebever-
ine and the adverse event profiles of the ramosetron group were 
comparable with those of the mebeverine.
3
Since IBS is defined as abdominal pain or discomfort that is 
improved with defecation,
13 the US Food and Drug Administra-
tion (FDA) requested to evaluate the 2 major IBS symptoms: ab-
dominal pain and defecation in IBS trials. Abdominal pain in-
tensity was recommended as the primary pain assessment and to 
be evaluated on a daily basis. For defecation component, the as-
sessment of stool frequency was encouraged for IBS-C and stool 
consistency for IBS-D.
14,15 In the present study, the primary effi-
cacy parameter was the patient-reported relief of IBS symptoms, 
including abdominal pain/discomfort and abnormal bowel habits, 
and the secondary endpoints were the changes in each symptom 
score. The IBS symptom scores and stool consistency were re-
corded daily throughout the study periods, and the changes of 
weekly mean scores were analyzed. This study is considered as a 
well-designed clinical study that was amenable to the proposal of 
the FDA for IBS clinical trials.
However, the present study had several limitations. First, be-
cause this study was not a placebo-controlled trial, the exact effi-
cacy of ramosetron over placebo was not evaluated. The FDA 
proposed that clinical studies need to be randomized and place-
bo-controlled to adequately assess IBS treatment benefits.
14,15 
Futhermore, mebeverine, the control agent in this study, showed 
no statistically significant benefit compared with placebo for 
global improvement of IBS symptoms in recent systematic 
reviews.
16-18 Thus, randomized placebo-controlled studies are 
necessary to estimate the exact effects of ramosetron in patients 
with IBS-D. Second, as the authors mentioned in discussion, be-
cause a tablet of ramosetron was taken once daily and a tablet of 
mebeveine was taken 3 times daily, the psychological effects 
might be greater in the patients who received mebeverine. 
Finally, this study was conducted for a short period and used only 
one dose of ramosetron. Further studies to evaluate the long-term 
effects of ramosetron and whether twice daily administration of a 
ramosetron 5 μg tablet has greater efficacy in patients with IBS-D 
are needed. 
Although several limitations exist, the present study is a 
well-designed, randomized clinical trial to assess the efficacy and 
safety of 5 μg ramosetron in male patients with IBS-D. Ramose-
tron can be used safely for the relief of IBS symptoms in male 
with IBS-D. Further studies on whether ramosetron is effective 
for female patients with IBS-D are warranted. 
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